About Celsion (NASDAQ:CLSN)
Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company's lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLSN
CUSIPN/A
Phone609-896-9100
Debt
Debt-to-Equity RatioN/A
Current Ratio3.93%
Quick Ratio3.93%
Price-To-Earnings
Trailing P/E Ratio-0.97
Forward P/E Ratio-1.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$500,000.00
Price / Sales82.31
Cash FlowN/A
Price / CashN/A
Book Value$1.66 per share
Price / Book1.40
Profitability
EPS (Most Recent Fiscal Year)($2.39)
Net Income$-20,400,000.00
Net Margins-4,030.49%
Return on Equity-163.12%
Return on Assets-54.46%
Miscellaneous
Employees21
Outstanding Shares17,740,000
Celsion (NASDAQ:CLSN) Frequently Asked Questions
What is Celsion's stock symbol?
Celsion trades on the NASDAQ under the ticker symbol "CLSN."
When did Celsion's stock split? How did Celsion's stock split work?
Shares of Celsion reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.
How were Celsion's earnings last quarter?
Celsion Co. (NASDAQ:CLSN) issued its quarterly earnings results on Thursday, May, 18th. The biotechnology company reported ($1.64) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.30) by $0.34. The biotechnology company had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.13 million. Celsion had a negative net margin of 4,030.49% and a negative return on equity of 163.12%. View Celsion's Earnings History.
When is Celsion's next earnings date?
What price target have analysts set for CLSN?
2 brokerages have issued 1-year price objectives for Celsion's stock. Their forecasts range from $7.00 to $9.00. On average, they anticipate Celsion's share price to reach $8.00 in the next twelve months. View Analyst Ratings for Celsion.
What are Wall Street analysts saying about Celsion stock?
Here are some recent quotes from research analysts about Celsion stock:
- 1. According to Zacks Investment Research, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. " (4/3/2018)
- 2. Maxim Group analysts commented, "Celsion announced that the company will present updated data from the P1b Ovation study evaluating GEN-1 (DNA-based IL-12) in advanced ovarian cancer at ASCO (American Society of Clinical Oncology, June 2-6, 2017)." (4/20/2017)
Who are some of Celsion's key competitors?
Some companies that are related to Celsion include MEI Pharma (MEIP), Alimera Sciences (ALIM), Xenon Pharmaceuticals (XENE), vTv Therapeutics (VTVT), Regulus Therapeutics (RGLS), Vascular Biogenics (VBLT), Axsome Therapeutics (AXSM), Sophiris Bio (SPHS), Eleven Biotherapeutics (EBIO), Arcturus Therapeutics (ARCT), Vernalis (VNLPY), Scynexis (SCYX), Versartis (VSAR), Pain Therapeutics (PTIE), Catabasis Pharmaceuticals (CATB), Zosano Pharma (ZSAN), Acerus Pharmaceuti (TRLPF) and Immutep (IMMP).
Who are Celsion's key executives?
Celsion's management team includes the folowing people:
- Mr. Michael H. Tardugno, Exec. Chairman, Pres & CEO (Age 67)
- Mr. Jeffrey W. Church, CFO, Sr. VP of Corp. Strategy & IR and Corp. Sec. (Age 61)
- Dr. Khursheed Anwer, Exec. VP & Chief Scientific Officer (Age 58)
- Dr. Nicholas Borys, Sr. VP & Chief Medical Officer (Age 59)
- Mr. Timothy J. Tumminello CPA, Chief Accounting Officer and Controller (Age 60)
Has Celsion been receiving favorable news coverage?
Media stories about CLSN stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Celsion earned a news impact score of 0.16 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 44.88 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Celsion?
Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Celsion's stock price today?
One share of CLSN stock can currently be purchased for approximately $2.32.
How big of a company is Celsion?
Celsion has a market capitalization of $39.92 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-20,400,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis. Celsion employs 21 workers across the globe.
How can I contact Celsion?
Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]
MarketBeat Community Rating for Celsion (CLSN)
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe CLSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Celsion (NASDAQ:CLSN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Celsion in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 244.83%. The high price target for CLSN is $9.00 and the low price target for CLSN is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $8.00 | $14.50 | $14.50 | $16.3333 |
| Price Target Upside: | 244.83% upside | 577.57% upside | 577.57% upside | 169.53% upside |
Celsion (NASDAQ:CLSN) Consensus Price Target History
Celsion (NASDAQ:CLSN) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Celsion (NASDAQ:CLSN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Celsion (NASDAQ CLSN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.40%
Institutional Ownership Percentage: 3.83%
Celsion (NASDAQ CLSN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/9/2018 | Michael H Tardugno | CEO | Buy | 2,500 | $2.30 | $5,750.00 | 20,200 |  |
| 3/5/2018 | Michael H Tardugno | CEO | Buy | 7,500 | $2.38 | $17,850.00 | 17,700 | |
| 2/22/2018 | Alberto R Martinez Jr | Director | Buy | 7,143 | $2.17 | $15,500.31 | 20,000 | |
| 2/20/2018 | Frederick J Fritz | Director | Buy | 6,000 | $2.17 | $13,020.00 | 12,841 | |
| 7/7/2017 | Frederick J Fritz | Director | Buy | 13,000 | $1.89 | $24,570.00 | 9,841 | |
| 2/21/2017 | Alberto R Martinez Jr | Director | Buy | 35,000 | $0.23 | $8,050.00 | 180,081 | |
| 2/15/2017 | Alberto R Martinez Jr | Director | Buy | 45,000 | $0.22 | $9,900.00 | 145,081 | |
| 11/14/2016 | Alberto R Martinez Jr | Director | Buy | 10,000 | $0.86 | $8,600.00 | 100,081 | |
| 11/11/2016 | Alberto R Martinez Jr | Director | Buy | 10,000 | $0.91 | $9,100.00 | 90,081 | |
| 10/7/2016 | Michael H Tardugno | Chairman | Buy | 10,000 | $1.14 | $11,400.00 | 143,021 | |
| 8/16/2016 | Alberto R Martinez Jr | Director | Buy | 5,000 | $1.25 | $6,250.00 | 80,081 | |
| 6/17/2016 | Alberto R Martinez Jr | Director | Buy | 5,000 | $1.35 | $6,750.00 | 75,081 | |
| 6/16/2016 | Michael H Tardugno | CEO | Buy | 7,500 | $1.35 | $10,125.00 | 128,021 | |
| 2/19/2016 | Michael H Tardugno | CEO | Buy | 3,000 | $1.27 | $3,810.00 | 120,521 | |
| 2/17/2016 | Michael H Tardugno | CEO | Buy | 2,000 | $1.27 | $2,540.00 | 117,521 | |
| 2/16/2016 | Alberto R Martinez Jr | Director | Buy | 5,000 | $1.16 | $5,800.00 | 70,081 | |
| 2/16/2016 | Michael H Tardugno | CEO | Buy | 4,500 | $1.20 | $5,400.00 | 115,521 | |
| 2/12/2016 | Michael H Tardugno | CEO | Buy | 6,500 | $1.13 | $7,345.00 | 111,021 | |
| 12/3/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 5,556 | $2.08 | $11,556.48 | 2,421,867 | |
| 11/30/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 20,000 | $2.15 | $43,000.00 | 2,442,423 | |
| 9/8/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 10,000 | $2.11 | $21,100.00 | 2,462,423 | |
| 8/17/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 10,000 | $2.19 | $21,900.00 | 2,472,423 | |
| 8/13/2015 | Egwu, Inc. Fka Egen, Inc. | Major Shareholder | Sell | 20,000 | $2.23 | $44,600.00 | | |
| 5/13/2015 | Alberto R Martinez Jr | Director | Buy | 5,000 | $2.50 | $12,500.00 | | |
| 12/18/2014 | Frederick J Fritz | Director | Buy | 4,000 | $2.34 | $9,360.00 | | |
| 11/13/2014 | Robert W Hooper | Director | Buy | 4,000 | $2.50 | $10,000.00 | | |
| 8/15/2014 | Alberto R Martinez Jr | Director | Buy | 5,000 | $3.12 | $15,600.00 | | |
| 8/15/2014 | Michael H Tardugno | CEO | Buy | 4,000 | $3.12 | $12,480.00 | | |
| 8/14/2014 | Frederick J Fritz | Director | Buy | 4,000 | $3.20 | $12,800.00 | | |
| 6/26/2014 | Alberto R Martinez Jr | Director | Buy | 5,000 | $3.36 | $16,800.00 | | |
| 6/11/2014 | Michael H Tardugno | CEO | Buy | 5,000 | $3.20 | $16,000.00 | | |
| 3/14/2014 | Frederick Fritz | Director | Buy | 2,500 | $3.86 | $9,650.00 | 21,331 | |
| 3/14/2014 | Michael Tardugno | CEO | Buy | 4,000 | $3.84 | $15,360.00 | 57,521 | |
| 11/19/2013 | Michael Tardugno | CEO | Buy | 2,800 | $3.59 | $10,052.00 | 53,521 | |
| 11/15/2013 | Frederick Fritz | Director | Buy | 3,000 | $3.80 | $11,400.00 | 14,331 | |
| 8/16/2013 | Frederick Fritz | Director | Buy | 10,000 | $1.09 | $10,900.00 | 51,000 | |
| 8/16/2013 | Michael Tardugno | CEO | Buy | 5,000 | $1.08 | $5,400.00 | 228,285 | |
| 6/12/2013 | Michael H Tardugno | CEO | Buy | 10,000 | $1.35 | $13,500.00 | | |
| 5/21/2013 | Alberto R Martinez Jr | Director | Buy | 5,000 | $0.93 | $4,650.00 | | |
| 5/13/2013 | Alberto R Martinez Jr | Director | Buy | 5,000 | $0.96 | $4,800.00 | | |
| 5/10/2013 | Alberto R Martinez Jr | Director | Buy | 5,000 | $0.92 | $4,600.00 | | |
| 3/20/2013 | Alberto R Martinez Jr | Director | Buy | 3,750 | $1.06 | $3,975.00 | | |
| 12/10/2012 | Max Link | Director | Buy | 14,000 | $7.60 | $106,400.00 | | |
| 11/15/2012 | Robert W Hooper | Director | Buy | 11,600 | $5.20 | $60,320.00 | | |
| 9/14/2012 | Michael H Tardugno | CEO | Buy | 5,000 | $5.03 | $25,150.00 | | |
| 9/10/2012 | Robert W Hooper | Director | Buy | 10,000 | $4.95 | $49,500.00 | | |
| 8/29/2012 | Robert W Hooper | Director | Buy | 2,500 | $4.65 | $11,625.00 | | |
(Data available from 1/1/2013 forward)
Celsion (NASDAQ CLSN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | International Liver Congress™ 2018 Symposium Highlights Celsion's ThermoDox® in Treatment of Primary Liver Cancer
globenewswire.com - April 12 at 10:53 AM |
 | International Liver Congress™ 2018 Symposium Highlights Celsion’s ThermoDox® in Treatment of Primary Liver Cancer
finance.yahoo.com - April 12 at 10:53 AM |
 | Form 4 Celsion CORP For: Apr 09 Filed by: Tardugno Michael H
www.streetinsider.com - April 9 at 4:07 PM |
| Celsion (CLSN) Says DMC Completes Planned Safety and Data Review of its Phase III OPTIMA Study of ThermoDox in ...
www.streetinsider.com - April 9 at 4:07 PM |
| Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion's Phase III OPTIMA Study of ...
globenewswire.com - April 9 at 10:23 AM |
| Data Monitoring Committee (DMC) Completes Planned Safety and Data Review of Celsion’s Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
finance.yahoo.com - April 9 at 10:23 AM |
 | Celsion (CLSN) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:54 PM |
| Celsion (CLSN) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - March 28 at 10:22 PM |
| Edited Transcript of CLSN earnings conference call or presentation 27-Mar-18 3:00pm GMT
finance.yahoo.com - March 28 at 10:01 AM |
| Celsion Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 27 at 10:11 AM |
| Celsion Co. (CLSN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 26 at 8:26 AM |
| Celsion (CLSN) Downgraded by ValuEngine to Strong Sell
www.americanbankingnews.com - March 25 at 7:32 PM |
| Celsion (CLSN) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 23 at 11:20 PM |
| Celsion (CLSN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 23 at 8:20 PM |
| $130,000.00 in Sales Expected for Celsion Co. (CLSN) This Quarter
www.americanbankingnews.com - March 21 at 8:49 AM |
| Celsion Corporation to Hold Year-End 2017 Financial Results Conference Call on Tuesday, March 27, 2018
finance.yahoo.com - March 20 at 9:51 AM |
| Celsion (CLSN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 19 at 11:48 PM |
| Critical Comparison: Celsion (CLSN) versus Edge Therapeutics (EDGE)
www.americanbankingnews.com - March 17 at 3:06 AM |
| Celsion (CLSN) Downgraded by ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM |
| Celsion Corporation to Present at Upcoming Investor Conferences
finance.yahoo.com - March 12 at 4:02 PM |
| Celsion Co. (CLSN) CEO Michael H. Tardugno Acquires 7,500 Shares
www.americanbankingnews.com - March 5 at 12:38 PM |
| Celsion Announces Ovarian Cancer Expert Presentation at Oppenheimer & Co. Investor Event
finance.yahoo.com - March 5 at 10:59 AM |
| Zacks: Analysts Anticipate Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - March 4 at 5:46 AM |
| -$0.31 EPS Expected for Celsion Co. (CLSN) This Quarter
www.americanbankingnews.com - March 2 at 12:08 PM |
| Celsion Co. (CLSN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 1 at 12:10 PM |
| Celsion Co. (CLSN) Director Purchases $15,500.31 in Stock
www.americanbankingnews.com - February 22 at 3:26 PM |
| Frederick J. Fritz Acquires 6,000 Shares of Celsion Co. (CLSN) Stock
www.americanbankingnews.com - February 21 at 12:31 PM |
| Analysts Expect Celsion Co. (CLSN) Will Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - February 15 at 3:36 AM |
| Zacks: Brokerages Expect Celsion Co. (CLSN) to Announce -$0.31 EPS
www.americanbankingnews.com - February 13 at 3:12 PM |
| Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association's 12th Annual ... - GlobeNewswire (press release)
globenewswire.com - February 13 at 6:01 AM |
| Celsion Announces ThermoDox® HEAT Study Presentation at Korean Liver Cancer Association’s 12th Annual Scientific Meeting
finance.yahoo.com - February 12 at 3:21 PM |
| Celsion Co. (CLSN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 4 at 8:02 AM |
| Celsion Co. (CLSN) Expected to Announce Quarterly Sales of $130,000.00
www.americanbankingnews.com - January 29 at 3:46 AM |
| Celsion Corporation Provides Corporate Update and 2018 Outlook
finance.yahoo.com - January 18 at 10:38 AM |
| Celsion (CLSN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - January 11 at 7:48 PM |
| Zacks: Analysts Anticipate Celsion Co. (CLSN) to Announce -$0.31 Earnings Per Share
www.americanbankingnews.com - January 10 at 5:28 PM |
| Celsion Co. (CLSN) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 10 at 8:18 AM |
 | Celsion's Phase I/II Cancer Study Initiation Gets FDA Nod - Nasdaq
www.nasdaq.com - January 5 at 4:54 PM |
 | FDA Win Sends Celsion Corporation (CLSN) Shares Higher - Investorplace.com
investorplace.com - January 5 at 4:54 PM |
| FDA Win Sends Celsion Corporation (CLSN) Shares Higher
investorplace.com - January 4 at 4:14 PM |
| Celsion Announces FDA Clearance of the OVATION II Study for the Evaluation of GEN-1 Immunotherapy to Treat Newly Diagnosed Stage III/IV Ovarian Cancer
finance.yahoo.com - January 4 at 9:41 AM |
| Celsion shares rise 20% after FDA clears its ovarian cancer therapy for a phase 1/2 trial
finance.yahoo.com - January 4 at 9:41 AM |
| Celsion Corporation (CLSN) Shares on the Rise; Here’s Why
finance.yahoo.com - January 4 at 9:41 AM |
| Zacks.com highlights: Hecla Mining, Cloud Peak Energy, Celsion, QuickLogic and Precision Drilling
finance.yahoo.com - January 4 at 9:41 AM |
| ETFs with exposure to Celsion Corp. : January 2, 2018
finance.yahoo.com - January 2 at 6:24 PM |
| Zacks: Brokerages Anticipate Celsion Co. (CLSN) Will Post Quarterly Sales of $130,000.00
www.americanbankingnews.com - December 27 at 1:40 PM |
| Brokerages Anticipate Celsion Co. (CLSN) to Post -$0.31 EPS
www.americanbankingnews.com - December 25 at 5:08 AM |
| ETFs with exposure to Celsion Corp. : December 22, 2017
finance.yahoo.com - December 22 at 8:55 PM |
| Celsion (CLSN) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - December 19 at 9:02 PM |
| Celsion Co. (CLSN) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 16 at 8:46 AM |
Celsion (NASDAQ:CLSN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Celsion (NASDAQ:CLSN) Income Statement, Balance Sheet and Cash Flow Statement
Celsion (NASDAQ CLSN) Stock Chart for Friday, April, 20, 2018
Loading chart…
